ZITHROMAX (azithromycin dihydrate) by Pfizer is drug. First approved in 2002.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
ZITHROMAX (azithromycin dihydrate) is an oral macrolide antibiotic approved in 2002 for bacterial infections. It works by inhibiting bacterial protein synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. Patients across multiple infection types rely on this established, well-tolerated agent.
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely transitioning to lifecycle management and generic transition planning, suggesting smaller but specialized teams focused on market defense.
drug. [see ]
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg
Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg
Zithromax EV in Community-Acquired Pneumonia (CAP)
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ZITHROMAX positions you in a mature product lifecycle phase where the skill set pivots from growth marketing to defense and transition planning. This role develops expertise in generic competition strategy, market consolidation, and lifecycle value extraction—valuable competencies for managing other LOE transitions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo